Description
Manufacturer
Novartis
Contents
Vildagliptin
Indication
Type 2 DM as monotherapy in patient inadequately controlled by diet & exercise alone & for whom metformin is inappropriate due to contraindication or intolerance.
Instruction
-
Take Galvus exactly as your doctor tells you to. Swallow the tablets with a drink of water.
-
Your doctor will tell you how many doses you should take and this information will also be printed on the label of the pack of tablets to remind you. If you have been told to take one dose of Galvus each day, take it in the morning. If you have been told to take two doses each day, take your first dose in the morning and the second dose in the evening. You can take the Galvus tablets before, during or after meals.
-
If you forget to take a dose, take it as soon as you remember (unless it is nearly time for your next dose, in which case leave out the missed dose). Do not take two doses together to make up for a forgotten dose.
Drug interaction
Vildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.
Combination with pioglitazone, metformin and glyburide: Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.
Digoxin (Pgp substrate), warfarin (CYP2C9 substrate): Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. However, this has not been established in the target population.
Combination with amlodipine, ramipril, valsartan or simvastatin: Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed after co-administration with vildagliptin.
Combination with ACE-inhibitors: There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors (see Adverse Reactions).
As with other oral antidiabetic medicinal products the hypoglycaemic effect of vildagliptin may be reduced by certain active substances including, thiazides, corticosteroids, thyroid products and sympathomimetics.
More detail about Complete Wellness
Malaysia
